Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.50 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.46 |
| ▸ | TET3 | O43151 | 2/20 | 0.46 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 3/20 | 0.44 |
| ▸ | KDM4A | O75164 | 2/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.44 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KDM6B | O15054 | 1/20 | 0.40 |
| ▸ | KDM5C | P41229 | 1/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.40 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.40 |
| ▸ | GLS | O94925 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4787354 | 0.79 | FOLH1 (0.40) | FOLH1 | |
| SCHEMBL7078225 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2TET2TET3TET1KDM2A | |
| SCHEMBL7078226 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2TET2TET3TET1KDM2A | |
| SCHEMBL7078228 | 0.77 | SMN1; SMN2 (0.52) | SMN1; SMN2TET2TET3TET1KDM2A | |
| SCHEMBL6412290 | 0.77 | ECE1 (0.41) | FOLH1 | |
| SCHEMBL19091220 | 0.75 | SMN1; SMN2 (0.44) | SMN1; SMN2FOLH1TET2TET3TET1 | |
| SCHEMBL27261680 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2TET2TET3TET1KDM2A | |
| SCHEMBL13589987 | 0.73 | SMN1; SMN2 (0.54) | SMN1; SMN2TET2TET3TET1KDM2A | |
| SCHEMBL3800895 | 0.73 | SMN1; SMN2 (0.48) | SMN1; SMN2TET2TET3TET1KDM2A | |
| SCHEMBL10596071 | 0.72 | FOLH1 (0.48) | FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | RAYZEBIO, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158179-A1 | RADIOPHARMACEUTICAL CONJUGATE COMPOSITIONS AND USES THEREOF | PAICS, LNPEP, DNPEP | SMN1; SMN2 2830/4885FOLH1 6/4885TET2 4004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.